Ultime notizie per Warby Parker (NYSE:WRBY) Azioni

WARBY PARKER INC-CLASS A

Warby Parker

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Warby Parker Inc

President Donald Trump's Liberation Day is living up to its name, though perhaps not in the way the administration envisioned. Thanks to last week's sweeping wave of tariffs, technical analysts have sounded the alarm about the potential for a <a href="https://www.benzinga.com/general/market-summary/25/04/44662164/us-stock-futures-slump-following-massive-tariff-induced-selloff-experts-warn-of-a-brewing-great-depression-like-pattern">steep downturn reminiscent of the Great Depression</a>. Adding to the anxieties is that precious few companies have been spared volatility, not even tech juggernaut NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
While the bulls are mounting a comeback effort on Monday, over the past five sessions, NVDA stock lost roughly 11%. Since the start of the year, equity has slipped 28%, reflecting a dramatic turn of events tied to the post-pandemic recovery. Throughout 2023 and especially 2024, Nvidia saw its valuation skyrocket thanks to demand for its graphics processors, which have undergirded the artificial intelligence revolution.
Unfortunately for the optimists, a combination of competitive pressures, new rivals in the AI ecosystem and unfavorable (at least for now) political frameworks have created a headwind for NVDA stock. As such, market makers are pricing in negative outcomes for NVDA options, which makes perfect sense. If analysts are mentioning the Great Depression, it's safe to say that sentiment is poor.
However, the pessimism has gotten so rough that the risk profile in certain option spreads has become inverted, so to speak. This backdrop is creating an enticing proposition for clever contrarians.
<h2 class="wp-block-heading">How To Lose And Still Win With NVDA Stock</h2>
For the typical bull call spread strategy — especially one underlying a strong business enterprise like Nvidia — the target equity must rise above a breakeven threshold to be profitable. This makes intuitive sense because the trader is paying a net debit to hopefully realize a specific outcome.
On the other hand, sellers of call spreads are essentially betting against this outcome materializing. These folks start their position from a cash influx because they receive a credit (the debit the call buyer is paying). As such, call spread sellers aren't necessarily hoping that the security falls in value. Rather, just moving sideways is often good enough for the seller to keep the entire premium received.
What makes the present circumstance unique is that the fear of volatility is so intense that relatively high-payout bull call spreads don't require NVDA stock to rise. Instead, it just can't fall too much, which is, frankly, a wildly compelling deal.
Take, for example, the 92/93 bull call spread for the options chain expiring this coming Friday. This transaction involves buying the $92 call (at a time-of-writing ask of $690) and simultaneously selling the $93 call (at a bid of $620). The proceeds from the short call partially offset the debit paid for the long call, resulting in a net cash outlay of $70.
Should NVDA stock stay at or above the short strike price at expiration, the maximum reward comes from the difference between the strike prices (multiplied by 100 shares) minus the cash outlay or $30. That's a payout of nearly 43% — and NVDA doesn't have to rise! Currently, the market price is above the short strike price, so NVDA can even decline and still qualify for the full reward.
Of course, the market fluctuates constantly, so exact parameters may change. But currently, because of the tariff turmoil, the risk profile in certain call spreads is inverted. Rather than a traditional debit structure, the aforementioned call spread acts almost like a credit spread—but to the benefit of the debit buyer.
<h2 class="wp-block-heading">The Compelling Math Behind the Risk Inversion</h2>
Based on pricing data since January 2019, the probability that any given week will be profitable is 56.13%. This is calculated by taking the number of up weeks divided by the total number of weeks in the dataset. As a baseline, then, the trader enjoys a house advantage when buying the aforementioned 92/93 bull spread expiring this week.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025-1024x576.jpg" alt="" class="wp-image-860524" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
However, the question isn't whether NVDA stock will rise this week or not. Rather, it's the odds that NVDA will not drop below $93, the short strike price of the aforementioned call spread. Mathematically, traders spotted a 2% safety margin relative to the time-of-writing price of around $95. Therefore, the odds are focused on whether NVDA will at least do better than lose 2% this week.
On any given week, the chance that Nvidia stock will perform better than a 2% loss is nearly 72%.
Granted, this isn't a pure arbitrage situation. There's still risk involved and no guarantee that this call spread will be profitable. If another unprecedented event materializes, then NVDA stock may collapse beyond the magnitude provided by the safety margin.
Still, the bottom line is that the house is giving gamblers both a robust payout and some wiggle room. Such combinations don't come around too often.
Photo: Shutterstock

Equities

Long Ideas

Options

Movers

NVDA

Options Corner: Trump 2.0 Trauma Sparks 'Risk Inverted' Nvidia Call Spreads

UBS analyst Joshua Spector maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Neutral and lowers the price target from $34 to $21.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on Olin, Lowers Price Target to $21

Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) revealed a new analysis of the pivotal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">RISE-PD Phase 3 study</a> on Monday.
The data showed that patients who converted to Crexont from immediate release (IR) carbidopa/levodopa (CD/LD) experienced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44664141/amneal-announces-new-data-from-phase-3-study-showing-significant-improvements-in-sleep-quality-wit" rel="noreferrer noopener">improved sleep quality</a>.
These improvements were measured by their Parkinson&#8217;s Disease Sleep Scale-2 (PDSS-2) total scores, showing a mean difference of -2.35 (p&lt;0.0001).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/44040038/generic-drugmaker-amneal-clocks-mixed-q4-earnings-plans-expansion-in-high-growth-areas-like-weight-loss-products-biosimilars" rel="noreferrer noopener">Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars</a>
Crexont, indicated for Parkinson&#8217;s disease (PD), is a novel CD/LD formulation that combines IR granules and extended-release pellets. This innovative design allows for rapid onset while leveraging a sustained-release polymer for slow LD release, potentially enabling longer LD absorption in the gut.
The new analysis showed that patients on Crexont, compared to IR CD/LD, also experienced statistically significant improvements across all PDSS-2 subdomains, including reduced disturbed sleep (-1.07, p&lt;0.0001), improved nighttime motor symptoms (‑0.62, p&lt;0.0059) and PD symptoms at night (-0.65, p&lt;0.0017).
A separate analysis of Hauser diary entries, a commonly used PD symptom tracking tool, from patients who completed the RISE-PD study will also be presented at AAN.
Treatment with CREXONT compared to IR CD/LD significantly increased the number of patients who reported waking up in an &#8220;On&#8221; state and patients who never recorded being in an &#8220;Off&#8221; state upon awakening.
Furthermore, the percentage of patients who never recorded &#8220;On&#8221; upon awakening decreased with Crexont vs. IR CD/LD.
Amneal has initiated a Phase 4 clinical trial, ELEVATE-PD, to evaluate the real-world efficacy and safety of CREXONT in patients with PD.
Price Action: AMRX stock is down 2.85% at $7.17 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44653345/bofa-analyst-forecasts-slower-growth-for-broker-stocks-as-market-volatility-increases" target="_blank" rel="noreferrer noopener">BofA Analyst Forecasts Slower Growth For Broker Stocks As Market Volatility Increases</a></li>
</ul>

Health Care

General

AMRX

Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients

UBS analyst Joshua Spector maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Neutral and lowers the price target from $41 to $29.

UBS Maintains Neutral on Dow, Lowers Price Target to $29

Treasury Secretary Scott Bessent To Lead U.S. Tariff Talks With Japan, With Yen On Agenda

UBS analyst Cleveland Rueckert maintains Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) with a Neutral and lowers the price target from $55 to $54.

BALL

UBS Maintains Neutral on Ball, Lowers Price Target to $54

UBS analyst Joshua Spector maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Neutral and lowers the price target from $207 to $189.

UBS Maintains Neutral on Avery Dennison, Lowers Price Target to $189

UBS analyst Ami Probandt initiates coverage on Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) with a Buy rating and announces Price Target of $24.

Initiation

UBS Initiates Coverage On Independence Realty Trust with Buy Rating, Announces Price Target of $24

Major cryptocurrencies are staging a slight recovery after a brutal Monday sell-off. The broader downturn in digital assets continues to mirror turbulence in traditional markets, as investors react to escalating geoeconomic tariff conflicts.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$78,891.70</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,564.21&nbsp;</td>
<td>-3.9%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$107.17</td>
<td>+1.4%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$1.91</td>
<td>-4.3%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1486</td>
<td>-3.3%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001141</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 17.9% and daily active addresses falling by 6.8%. Transactions greater than $100,000 are up from 6,738 to 7,593 in a single day. Exchanges netflows are down by 192.6%.</li>
<li>Coinglass data reports 432,028 traders were liquidated in the past 24 hours for $1.46 billion.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44671650/strategy-reports-59-billion-in-unrealized-bitcoin-losses-pauses-new-purchases">Strategy Reports $5.9 Billion in Unrealized Bitcoin Losses, Pauses New Purchases</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44668202/bitcoin-ethereum-xrp-drowning-in-tariff-tsunami-fall-to-50000-possible-expert-warns">Bitcoin, Ethereum, XRP Drowning In Tariff Tsunami: &#8216;Fall To $50,000&#8217; Possible, Expert Warns</a></li>
<li><a href="https://www.benzinga.com/25/04/44670948/bitcoin-but-make-it-bounded-first-trust-launches-risk-buffered-crypto-etfs">New ETFs Offer Bitcoin Exposure With Built-In Safety Nets</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44670683/peter-schiff-says-trumps-tariffs-are-dumber-than-a-strategic-bitcoin-reserve">Peter Schiff Says Trump&#8217;s Tariffs Are &#8216;Dumber Than A Strategic Bitcoin Reserve&#8217;</a></li>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44667607/tether-just-bought-8888-bitcoin-for-750m-what-do-the-charts-show-2">Tether Just Bought 8,888 Bitcoin for $750M – What Do the Charts Show?</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>SPX6900 (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SPX</a>)</td>
<td>$0.4924</td>
<td>+23.2%</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>$0.5133</td>
<td>+21%</td>
</tr>
<tr>
<td>DeXe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">DEXE</a>)</td>
<td>$15.62</td>
<td>+7.8%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader ShardiB2 believes Bitcoin will &#8220;at least test $80,000,&#8221; highlighting the area as a significant resistance level.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> has to at least test 80k&#8230; a lot of resistance there <a href="https://t.co/fnq140W55Q">pic.twitter.com/fnq140W55Q</a>
&mdash; Don&#39;t follow Shardi B if you hate Money (@ShardiB2) <a href="https://twitter.com/ShardiB2/status/1909306261092344005?ref_src=twsrc%5Etfw">April 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Javon Marks <a href="https://x.com/JavonTM1/status/1909268900639862827">points</a> to a consistent pattern of bullish signals throughout Bitcoin's major price movements—from $16,000 to a projected $109,000. He notes similar strength at prior key dips around $20,000, $38,000, and $49,000, now surfacing again near $74,000.
While Cryptomist <a href="https://x.com/Thecryptomist/status/1909298691690688999">sees</a> Bitcoin struggling to break past $81,500, he believes the reversal from $72,000 remains intact. Castillo Trading expects further choppy price action in the short term, suggesting an ideal trading range between $74,000 and $86,000 as uncertainty from tariff-related developments keeps market sentiment cautious.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Even though we have seen a lot of red recently. Still in the mindset of choppy price action continuing. Range between $86k-$74k would be amazing to trade. Still uncertainty across all markets, anything tariff related causing a reaction.<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/Yi0YG35sgs">pic.twitter.com/Yi0YG35sgs</a>
&mdash; Castillo Trading (@CastilloTrading) <a href="https://twitter.com/CastilloTrading/status/1909306938107871488?ref_src=twsrc%5Etfw">April 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Super Bitcoin Bro <a href="https://x.com/SuperBitcoinBro/status/1909301337386524781">notes</a> the current correction is milder than last summer's and remains above key technical levels, including the 50-day EMA and SMA. He asserts that "nothing about this screams cycle is over," and sees a 100% gain from here as far more likely than a 50% drop.
Despite the red candles, the tone from leading traders remains cautiously optimistic, with Bitcoin's macro trend still firmly bullish.
Read Next:&nbsp;
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44664638/millionaire-crypto-trader-reacts-to-bitcoin-mega-crash-you-have-only-one-job-here-survive">Millionaire Crypto Trader Reacts To Bitcoin Mega-Crash: &#8216;You Have Only One Job Here: Survive&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DEXE

$DOGE

$ETH

$SHIB

$SOL

$SPX

$XRP

Bitcoin, Ethereum, XRP, Dogecoin See Modest Rebound After Monday's Sell-Off

Technology and Communications Services stocks are outpacing the broader market on Monday amid a volatile session for U.S. equities <a href="https://www.benzinga.com/news/25/04/44671308/stock-market-surge-evaporates-as-headline-roulette-plagues-traders-fake-news-white-house-says-in-response-to-90-day-tariff-pause">related to tariff headlines</a>.
What Happened: The SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) continues to trade with high levels of volatility after President Donald Trump announced sweeping tariffs last week, raising concerns over higher prices for consumers, softening demand and a potential recession.&nbsp;
The SPDR Select Technology Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) is outpacing the broader market alongside the SPDR Select Communication Services Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>). The three largest holdings in the SPDR Technology fund are Apple, Microsoft and Nvidia. Meta, Alphabet and Google are the three largest weightings in the SPDR Communications fund. 
Trump&#8217;s tariff announcement last week sent markets tumbling as investors feared that other countries would retaliate against the new duties. Markets continued to fall on Monday, entering bear market territory as the Trump administration showed an unwillingness to budge on tariffs. 
Stocks briefly staged a massive reversal in early trading Monday after headlines circled suggesting Trump was considering a 90-day pause on tariffs. It&#8217;s not clear where the headlines originated from, but White House press secretary Karoline Leavitt confirmed the reports were false Monday morning, calling the headlines <a href="https://www.benzinga.com/news/25/04/44671308/stock-market-surge-evaporates-as-headline-roulette-plagues-traders-fake-news-white-house-says-in-response-to-90-day-tariff-pause">&#8220;fake news.&#8221;</a>
China on Friday responded to Trump with 34% tariffs on U.S. imports, export curbs on some rare earths and restrictions on several U.S. organizations, deepening the trade war between the world&#8217;s two largest economies. 
Ministers in the European Union are meeting on Monday to discuss how to respond to Trump&#8217;s tariffs, per Reuters. Trump has brushed off concerns about his sweeping tariff announcement. He also appeared to show little concern for the massive stock market losses over recent sessions.
&#8220;I don&#8217;t want anything to go down. But sometimes you have to take medicine to fix something,&#8221; Trump reportedly told reporters aboard Air Force One over the weekend.&nbsp;
Price Action: At the time of publication, the SPDR Select Technology Fund was up 0.98% at $184.15, while the SPY was up just 0.07% at $505.70. The SPDR Select Communication Services Fund was up 1.03% at $88.13 at last check, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44670683/peter-schiff-says-trumps-tariffs-are-dumber-than-a-strategic-bitcoin-reserve">Peter Schiff Says Trump&#8217;s Tariffs Are &#8216;Dumber Than A Strategic Bitcoin Reserve&#8217;</a></li>
</ul>
Photo: Shutterstock.

Technology, Communications Services Stocks Are Outpacing Broader Markets Monday: What's Going On?

Financial giants have made a conspicuous bearish move on PepsiCo. Our analysis of options history for PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) revealed 39 unusual trades.
Delving into the details, we found 35% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 23 were puts, with a value of $2,346,090, and 16 were calls, valued at $638,673.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $200.0 for PepsiCo over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for PepsiCo's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of PepsiCo's whale activity within a strike price range from $90.0 to $200.0 in the last 30 days. 
<h3>PepsiCo Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744052517_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$14.35</td>
<td>$13.65</td>
<td>$13.65</td>
<td>$155.00</td>
<td>$685.9K</td>
<td>5.2K</td>
<td>510</td>
</tr>
<tr>
<td>PEP</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$2.16</td>
<td>$1.78</td>
<td>$1.99</td>
<td>$100.00</td>
<td>$337.3K</td>
<td>1.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>PEP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.97</td>
<td>$2.97</td>
<td>$2.97</td>
<td>$141.00</td>
<td>$297.8K</td>
<td>183</td>
<td>1.0K</td>
</tr>
<tr>
<td>PEP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$24.35</td>
<td>$22.85</td>
<td>$23.2</td>
<td>$160.00</td>
<td>$157.7K</td>
<td>1.4K</td>
<td>2</td>
</tr>
<tr>
<td>PEP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$8.15</td>
<td>$7.9</td>
<td>$8.15</td>
<td>$145.00</td>
<td>$140.9K</td>
<td>3.2K</td>
<td>183</td>
</tr>
</tbody>
</table>

<h3>About PepsiCo</h3>
PepsiCo is a global leader in snacks and beverages, owning well-known household brands including Pepsi, Mountain Dew, Gatorade, Lay's, Cheetos, and Doritos, among others. The company dominates the global savory snacks market and also ranks as the second-largest beverage provider in the world (behind Coca-Cola) with diversified exposure to carbonated soft drinks, or CSD, as well as water, sports, and energy drink offerings. Convenience foods account for approximately 55% of its total revenue, with beverages making up the rest. Pepsi owns the bulk of its manufacturing and distribution capacity in the US and overseas. International markets made up 40% of both total sales and operating profits in 2024.
After a thorough review of the options trading surrounding PepsiCo, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>PepsiCo's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 9,176,424, the PEP's price is down by -1.9%, now at $143.83. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 17 days.</li>
</ul>
<h3>What Analysts Are Saying About PepsiCo</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $163.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Barclays lowers its rating to Equal-Weight with a new price target of $156. 
&#x2A; An analyst from Jefferies downgraded its action to Hold with a price target of $170. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest PepsiCo options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Markets

PepsiCo's Options: A Look at What the Big Money is Thinking

Deep-pocketed investors have adopted a bullish approach towards Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ISRG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 64 extraordinary options activities for Intuitive Surgical. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 34% bearish. Among these notable options, 52 are puts, totaling $6,403,431, and 12 are calls, amounting to $815,890.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $390.0 to $700.0 for Intuitive Surgical over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Intuitive Surgical options trades today is 139.17 with a total volume of 1,748.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Surgical's big money trades within a strike price range of $390.0 to $700.0 over the last 30 days.
<h3>Intuitive Surgical Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744052512_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$134.2</td>
<td>$131.6</td>
<td>$132.55</td>
<td>$580.00</td>
<td>$662.7K</td>
<td align="right">232</td>
<td align="right">161</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$136.7</td>
<td>$134.0</td>
<td>$134.0</td>
<td>$580.00</td>
<td>$549.4K</td>
<td align="right">232</td>
<td align="right">61</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$27.2</td>
<td>$27.1</td>
<td>$27.2</td>
<td>$430.00</td>
<td>$533.2K</td>
<td align="right">118</td>
<td align="right">248</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$99.5</td>
<td>$94.2</td>
<td>$97.24</td>
<td>$540.00</td>
<td>$486.1K</td>
<td align="right">215</td>
<td align="right">60</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$92.8</td>
<td>$91.3</td>
<td>$91.3</td>
<td>$540.00</td>
<td>$456.5K</td>
<td align="right">452</td>
<td align="right">53</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.
<h3>Current Position of Intuitive Surgical</h3>
<ul>
<li>With a volume of 2,792,565, the price of ISRG is up 3.21% at $466.08. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 15 days.</li>
</ul>
<h3>What Analysts Are Saying About Intuitive Surgical</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $602.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Intuitive Surgical, targeting a price of $605. 
&#x2A; An analyst from Baird persists with their Outperform rating on Intuitive Surgical, maintaining a target price of $600. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ISRG

A Closer Look at Intuitive Surgical's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bullish stance on Bank of America.
Looking at options history for Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) we detected 132 trades.
If we consider the specifics of each trade, it is accurate to state that 59% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 75 are puts, for a total amount of $6,910,848 and 57, calls, for a total amount of $7,447,285.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $18.0 to $50.0 for Bank of America over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Bank of America's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bank of America's whale trades within a strike price range from $18.0 to $50.0 in the last 30 days. 
<h3>Bank of America 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744052508_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.65</td>
<td>$5.4</td>
<td>$5.55</td>
<td>$35.00</td>
<td>$555.0K</td>
<td>10.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.6</td>
<td>$8.5</td>
<td>$8.6</td>
<td>$42.00</td>
<td>$164.2K</td>
<td>40.9K</td>
<td>86</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$12.3</td>
<td>$11.95</td>
<td>$12.3</td>
<td>$25.00</td>
<td>$159.8K</td>
<td>210</td>
<td>490</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$37.00</td>
<td>$147.0K</td>
<td>34.9K</td>
<td>6.9K</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.55</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$37.00</td>
<td>$138.0K</td>
<td>34.9K</td>
<td>7.7K</td>
</tr>
</tbody>
</table>

<h3>About Bank of America</h3>
Bank of America is one of the largest financial institutions in the United States, with more than $3.2 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
<h3>Bank of America's Current Market Status</h3>
<ul>
<li>With a trading volume of 98,544,583, the price of BAC is up by 3.56%, reaching $35.62.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 8 days from now.</li>
</ul>
<h3>Expert Opinions on Bank of America</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $49.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Bank of America, which currently sits at a price target of $48. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Bank of America with a target price of $50. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Bank of America, maintaining a target price of $56. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Bank of America with a target price of $50. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Bank of America, targeting a price of $43. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bank of America options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Behind the Scenes of Bank of America's Latest Options Trends

UBS analyst Joshua Spector maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Neutral and lowers the price target from $86 to $64.

UBS Maintains Neutral on Albemarle, Lowers Price Target to $64

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $386.69, along with a high estimate of $490.00 and a low estimate of $243.00. Experiencing a 4.38% decline, the current average is now lower than the previous average price target of $404.42. 
<img src="https://www.benzinga.com/files/images/story/2025/1744052463_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Caterpillar among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Steven Fisher &#x7C;UBS &#x7C;Lowers &#x7C;Sell &#x7C; $243.00&#x7C;$385.00 &#x7C; 
&#x7C;David Raso &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;In-Line &#x7C; $375.00&#x7C;$365.00 &#x7C; 
&#x7C;Michael Shlisky &#x7C;DA Davidson &#x7C;Raises &#x7C;Neutral &#x7C; $357.00&#x7C;$350.00 &#x7C; 
&#x7C;Jamie Cook &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $438.00&#x7C;$455.00 &#x7C; 
&#x7C;Steven Fisher &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $385.00&#x7C;$355.00 &#x7C; 
&#x7C;Kyle Menges &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $430.00&#x7C;$420.00 &#x7C; 
&#x7C;Tami Zakaria &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $490.00&#x7C;$515.00 &#x7C; 
&#x7C;Michael Feniger &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $414.00&#x7C;$452.00 &#x7C; 
&#x7C;Angel Castillo &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $300.00&#x7C;$330.00 &#x7C; 
&#x7C;Steven Fisher &#x7C;UBS &#x7C;Raises &#x7C;Sell &#x7C; $355.00&#x7C;$295.00 &#x7C; 
&#x7C;Jamie Cook &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $455.00&#x7C;$471.00 &#x7C; 
&#x7C;Kyle Menges &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $420.00&#x7C;$460.00 &#x7C; 
&#x7C;David Raso &#x7C;Evercore ISI Group &#x7C;Announces &#x7C;In-Line &#x7C; $365.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Caterpillar. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Caterpillar compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Caterpillar's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Caterpillar's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Caterpillar analyst ratings.</a>
<h2>All You Need to Know About Caterpillar</h2>
Caterpillar is the world's leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. Its reporting segments are: construction industries (40% sales/47% operating profit, or OP), resource industries (20% sales/19% OP), and energy &amp; transportation (40% sales/34% OP). Market share approaches 20% across many products. Caterpillar operates a captive finance subsidiary to facilitate sales. The firm has global reach (46% US sales/54% ex-US). Construction skews more domestic, while the other divisions are more geographically diversified. An independent network of 156 dealers operates approximately 2,800 facilities, giving Caterpillar reach into about 190 countries for sales and support services.
<h3>Caterpillar's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Decline in Revenue: Over the 3M period, Caterpillar faced challenges, resulting in a decline of approximately -5.01% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Caterpillar's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.21% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Caterpillar's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.35% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Caterpillar's ROA stands out, surpassing industry averages. With an impressive ROA of 3.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Caterpillar's debt-to-equity ratio stands notably higher than the industry average, reaching 1.97. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Caterpillar: Insights From 13 Financial Analysts

Analysts' ratings for Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $92.67, a high estimate of $105.00, and a low estimate of $84.00. Witnessing a positive shift, the current average has risen by 3.45% from the previous average price target of $89.58.
<img src="https://www.benzinga.com/files/images/story/2025/1744052446_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Nasdaq. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Benjamin Budish &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $87.00&#x7C;$95.00 &#x7C; 
&#x7C;Craig Siegenthaler &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $105.00&#x7C;$103.00 &#x7C; 
&#x7C;Alex Kramm &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $89.00&#x7C;$79.00 &#x7C; 
&#x7C;Ashish Sabadra &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $95.00&#x7C;$95.00 &#x7C; 
&#x7C;Michael Cho &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $95.00&#x7C;$88.00 &#x7C; 
&#x7C;Benjamin Budish &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $95.00&#x7C;$96.00 &#x7C; 
&#x7C;Owen Lau &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $89.00&#x7C;$86.00 &#x7C; 
&#x7C;Benjamin Budish &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $96.00&#x7C;$97.00 &#x7C; 
&#x7C;Christopher Allen &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $84.00&#x7C;$78.00 &#x7C; 
&#x7C;Patrick O'Shaughnessy&#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $84.00&#x7C;$83.00 &#x7C; 
&#x7C;Ashish Sabadra &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $95.00&#x7C;$95.00 &#x7C; 
&#x7C;Brian Bedell &#x7C;Deutsche Bank &#x7C;Raises &#x7C;Buy &#x7C; $98.00&#x7C;$80.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nasdaq. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Nasdaq's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nasdaq's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Unveiling the Story Behind Nasdaq</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as the firm seeks to become a diversified technology company.
<h3>Unraveling the Financial Story of Nasdaq</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Nasdaq's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 23.25%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nasdaq's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 17.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nasdaq's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Nasdaq's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.16%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.88.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NDAQ

Expert Outlook: Nasdaq Through The Eyes Of 12 Analysts

Analysts' ratings for Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $24.86, a high estimate of $28.00, and a low estimate of $22.00. This current average has decreased by 9.37% from the previous average price target of $27.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1744052438_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Regions Finl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Betsy Graseck &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $22.00&#x7C;$29.00 &#x7C; 
&#x7C;Vivek Juneja &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $23.00&#x7C;$26.00 &#x7C; 
&#x7C;Whit Mayo &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $26.00&#x7C;$28.00 &#x7C; 
&#x7C;Keith Horowitz &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $25.00&#x7C;$28.00 &#x7C; 
&#x7C;Brian Foran &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $24.00&#x7C;$26.00 &#x7C; 
&#x7C;Keith Horowitz &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $28.00&#x7C;$30.00 &#x7C; 
&#x7C;Brandon King &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $26.00&#x7C;$25.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regions Finl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Regions Finl compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Regions Finl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Regions Finl's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Regions Finl analyst ratings.</a>
<h2>Delving into Regions Finl's Background</h2>
Regions Financial is a regional bank based in Alabama, with branches primarily in the Southeastern and Midwestern United States. Regions primarily provides traditional commercial and retail banking and also offers mortgage services, asset management, wealth management, securities brokerage, and trust services.
<h3>Unraveling the Financial Story of Regions Finl</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Regions Finl displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 0.22%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Regions Finl's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 27.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Regions Finl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.07% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Regions Finl's ROA excels beyond industry benchmarks, reaching 0.32%. This signifies efficient management of assets and strong financial health.
Debt Management: Regions Finl's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.4.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Regions Finl: Insights From 7 Financial Analysts

Immunocore Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $75.67, a high estimate of $100.00, and a low estimate of $33.00. Experiencing a 0.72% decline, the current average is now lower than the previous average price target of $76.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1744052431_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Immunocore Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Graig Suvannavejh &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $33.00&#x7C;$38.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Gil Blum &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $71.00&#x7C;$71.00 &#x7C; 
&#x7C;Andrew Galler &#x7C;Morgan Stanley &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $35.00&#x7C;$35.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Gil Blum &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $71.00&#x7C;$71.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Gil Blum &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $71.00&#x7C;$71.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Immunocore Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Immunocore Holdings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Immunocore Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Immunocore Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IMCR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Immunocore Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Immunocore Holdings</h2>
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
<h3>Immunocore Holdings: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Immunocore Holdings's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 19.8%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Immunocore Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -28.28%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Immunocore Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -6.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Immunocore Holdings's ROA excels beyond industry benchmarks, reaching -2.27%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.2, Immunocore Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IMCR

Analyst Expectations For Immunocore Holdings's Future

Antero Resources's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) short percent of float has risen 54.62% since its last report. The company recently reported that it has 14.73 million shares sold short, which is 6.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Antero Resources Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744052427_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Antero Resources has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Antero Resources's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Antero Resources's peer group average for short interest as a percentage of float is 8.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About Antero Resources?

LONDON, April 07, 2025 (GLOBE NEWSWIRE) -- Sports.com, a global leader in digital sports entertainment and a wholly-owned brand of Lottery.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>, LTRYW))), has announced a partnership with Orange Middle East and Africa S.A. to provide sports video streaming and news content on Max it, Orange's revolutionary super-app. This collaboration marks a significant milestone in Sports.com's global growth strategy, offering millions of users across Africa and the Middle East access to premier sports content.
Building on the success of its My Orange and Orange Money applications—used by over 22 million customers daily—Orange launched Max it, an innovative super-app designed to transform digital engagement across Africa and the Middle East. Developed by the Orange teams in Africa specifically for the region, Max it integrates telecommunications, financial services, and e-commerce into a single, user-friendly interface—simplifying daily life for millions.
As part of its strategy to deliver a comprehensive digital experience, Max it now incorporates Sports.com's offerings—introducing world-class sports content into its growing ecosystem. Users can now access live sports coverage, real-time updates, 24/7 news, and exclusive documentaries—bringing the excitement of sports directly to their fingertips. This collaboration reinforces Sports.com's commitment to delivering localized and accessible sports content, aligning with Max it's mission to simplify and enhance everyday life.

Contracts

LTRY

Lottery.Com Announces Major Deal With Telecom Giant Orange To Bring Sports Streaming To Millions Across Africa And The Middle East

Press Releases

Warby Parker to Announce Second Quarter 2024 Financial Results on August 8, 2024

Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

Warby Parker Announces Second Quarter 2024 Results

Warby Parker Announces Participation in the Goldman Sachs 31st Annual Global Retailing Conference

Warby Parker to Announce Third Quarter 2024 Financial Results November 7, 2024

Warby Parker Announces Third Quarter 2024 Results

Warby Parker Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

Warby Parker to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Warby Parker Announces Fourth Quarter and Full Year 2024 Results

Target and Warby Parker Team Up to Bring Stylish, Affordable Eyewear to More Consumers

WRBY

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports

BARK

Build-A-Bear Workshop

Bath & Body Works

Barnes & Noble Education, Inc Common Stock

Barnes & Noble Education

Chewy

Dick's Sporting Goods

Envela

National Vision Holdings, Inc. - Common Stock

National Vision Holdings

Five Below

1-800-FLOWERS.COM, Inc. - Class A Common Stock

1-800-Flowers.com

Grove Collaborative Holdings, Inc. Class A Common Stock

Grove Collaborative Hldgs

MarineMax

Leslies

PetMed Express

Park Ha Biological Technology Co., Ltd. - ordinary shares

Park Ha Biological Tech

Sally Beauty Holdings, Inc. (Name to be changed from Sally Holdings, Inc.) Common Stock

Comments

Warby Parker

Notizie

Ultime notizie per Warby Parker (NYSE:WRBY) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO